Kali Inc. (KALY)

[BottomTurn]

$1 Million 2019 Revenue Target From Parallel Revenue Strategy

KALY is not relying on its biopharmaceutical development strategy alone to insure the company’s long-term success.  With the popularity of cannabis extracts for infusion into various consumer products, KALY’s patented extraction process offers arguably the highest quality extract to the infusion market.  Drawing on KALY’s patented cannabis extraction expertise, Puration’s (USOTC: PURA) EVERx CBD Sports Water is already the leading CBD infused beverage for the sports nutrition market.  KALY has also introduced its own CBD confections line, Hemp4mula with CBD infused gum already on the market and gummies on the way.  Hemp4mula is expected to be available on the Ecommerce site USMJ.com hosted by North American Cannabis Holdings, Inc. (USOTC: USMJ) (aka USMJ).  KALY has also entered into a partnership with Nouveau (USOTC: NOUV), a cannabis cultivation company, with plans to develop a proprietary cannabis cultivar that can further enhance the quality of KALY’s extracts.  KALY’s consumer revenue strategy offers a business line that can stand alone, but one that also provides KALY with the long-term staying power to take the necessary time to bring its cannabis extract biopharmaceutical products to market.  Currently, KALY management anticipates that its $1 million 2019 revenue goal for its parallel consumer market strategy is well within reach.